InMed Pharmaceuticals INM Estimates

NASDAQ INM
$1.39 +0.01 (+1.09%)
As of: Sep 22, 2026 · 12:39 PM EDT
Analyst Estimates

InMed Pharmaceuticals Inc. Revenue Estimates

Periods 13
Next Period Q1 26
Consensus 1.13 M

Analysts expect InMed Pharmaceuticals Inc. to report revenue of 1.13 M for Q1 26, against a range of 1.05 M to 1.21 M. The most recent reported quarter, Q4 25, came in at 820,188.00, a 40.1% miss against the 1.37 M consensus.

Metric Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Reported (Actual) 2.31 M901,860.001.24 M1.17 M1.29 M1.26 M1.11 M1.26 M820,188.00----
High Estimate 1.49 M1.53 M1.12 M1.54 M1.75 M---1.43 M1.21 M1.13 M1.44 M784,529.81
Low Estimate 1.23 M1.38 M1.02 M1.33 M1.61 M---1.31 M1.05 M1.00 M1.25 M658,555.67
Consensus Estimate 1.36 M1.46 M1.07 M1.44 M1.68 M---1.37 M1.13 M1.07 M1.35 M721,542.74
Analyst Estimates

InMed Pharmaceuticals Inc. Earnings Per Share (EPS) Estimates

Periods 13
Next Period Q4 23
Consensus -89.24

Analysts expect InMed Pharmaceuticals Inc. to report earnings per share of -89.24 for Q4 23, against a range of -97.57 to -80.91. The most recent reported quarter, Q2 26, came in at -1.40, a 113.6% miss against the 10.35 consensus.

Metric Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Reported (Actual) --15.20-3.80-3.602.40-2.71-3.64-1.94-0.51-0.73-1.40--
High Estimate -80.91-------15.7524.6111.194.2066.51
Low Estimate -97.57-------12.9322.559.513.7854.69
Consensus Estimate -89.24-------14.3423.5810.353.9960.60

InMed Pharmaceuticals Inc. Estimates API

Pull Wall Street consensus for InMed Pharmaceuticals Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=INM&mode=revenue&api_key=YOUR_API_KEY